Cystectomy/*methods Humans Organ Sparing Treatments/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery Bladder preservation High-grade non-muscle-invasive bladder cancer Meta-analysis Radical cystectomy PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Female Humans Male Prospective Studies *Quality of Life Urinary Bladder Neoplasms/drug therapy/*psychology/radiotherapy Bladder cancer Chemotherapy Muscle-invasive bladder cancer Quality of life Urothelial cancer PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

膀胱肿瘤 药物疗法 联合 泌尿外科手术 化学疗法 辅助 Meta分析

Body mass index diet dietary supplements prognosis urinary bladder cancer

膀胱肿瘤 化学疗法 肿瘤 局部灌注 Meta分析 肿瘤复发 局部

Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

Depression anxiety bladder cancer prevalence systematic review

Circulating Tumor DNA/*analysis/blood/urine Humans Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/pathology CfDNA biomarkers diagnosis meta-analysis

Periodontal diseases cohort studies meta-analysis periodontitis urinary bladder neoplasms

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Biomarkers Tumor/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*urine Biomarker Bladder cancer Diagnosis Systematic review Urine

Adult Case-Control Studies Child Environmental Exposure/*adverse effects/analysis Humans Odds Ratio Risk Factors Tobacco Smoke Pollution/*adverse effects/analysis Urinary Bladder Neoplasms/*epidemiology Workplace bladder cancer exposure to environmental tobacco smoke lifetime exposure meta-analysis

bladder cancer chemotherapy cystectomy muscle-invasive systematic review of interest.

Cisplatin/*therapeutic use Female Humans Male Neoadjuvant Therapy/*methods Urinary Bladder/drug effects/pathology Urinary Bladder Neoplasms/*drug therapy/pathology

Biomarkers Tumor/*urine Fibronectins/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/urine Biomarker Bladder cancer Diagnosis Meta-analysis Urine fibronectin standards of institutional and international research committee this article is based on previous published studies thus it does not contain any studies with human participants or animals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Aged *Coffee Cohort Studies Female Follow-Up Studies Humans Incidence Japan/epidemiology Male Middle Aged Prospective Studies Risk Factors Surveys and Questionnaires Urinary Bladder Neoplasms/diagnosis/*epidemiology/*prevention & control

UCA lncRNA 尿路上皮癌

Africa South of the Sahara Carcinoma Squamous Cell/ethnology/*pathology/therapy Carcinoma Transitional Cell/ethnology/*pathology/therapy Humans Urinary Bladder Neoplasms/ethnology/*pathology/therapy Africa bladder carcinoma squamous cell carcinoma transitional cell carcinoma

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy